Previous 10 | Next 10 |
Topics include safety data from the AMX0035 U.S. Expanded Access Program, progress on the development of an ALS diagnostic biomarker test, new in vitro data on AMX0114, and more Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today...
2023-09-25 17:15:50 ET Gainers: Pliant Therapeutics ( NASDAQ: PLRX ) +8% . ARS Pharmaceuticals ( SPRY ) +6% . Amylyx Pharmaceuticals ( AMLX ) +4% . Seres Therapeutics ( MCRB ) +2% . Pulmonx Corporation ( LUNG ) +2% . Lo...
2023-09-11 08:19:33 ET Summary Amylyx Pharmaceuticals is a small biotech company focused on developing therapies for neurodegenerative diseases. Their FDA-approved product, Relyvrio, is used to treat amyotrophic lateral sclerosis, a fatal neurodegenerative disorder. AMLX stock...
2023-08-14 05:45:30 ET Summary Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could po...
2023-08-11 16:10:14 ET Summary Amylyx Pharmaceuticals, focusing on ALS treatment, has shown significant financial growth with its product Relyvrio; seeking global expansion. Amylyx's impressive Q2 financial performance indicates profitability, negligible debt, and notable cash res...
2023-08-10 18:43:04 ET Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2023 Earnings Conference Call August 10, 2023 04:30 PM ET Company Participants Lindsey Allen - Head of Investor Relations & Communications Justin Klee - Co-Chief Executive Officer Margaret Olinger ...
2023-08-10 16:30:31 ET Amylyx Pharmaceuticals press release ( NASDAQ: AMLX ): Q2 GAAP EPS of $0.31 beats by $0.35 . Revenue of $98.2M beats by $6.06M . For further details see: Amylyx Pharmaceuticals GAAP EPS of $0.31 beats by $0.35, revenue of $98.2M bea...
Second quarter 2023 product revenue of $98.2 million; demand and insurance coverage for RELYVRIO ® in U.S. and ALBRIOZA™ in Canada continued to grow Strong financial position supported by $22.1 million of net income during the second quarter of 2023 and cash, cash equi...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its second quarter 2023 financial results on Thursday, August 10, 2023, following the close of the U.S. financial markets. Amylyx’ senior management team will host a conference c...
2023-07-28 12:56:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clinical trials can be like a tightrope over a minefield for biotech investors. Only a fraction of drugs even succeed through clinical trials to receive FDA approval. But for those that do,...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...